Abstract
This article explores the role of PET in the diagnosis and treatment of schizophrenia. PET imaging can reveal neurobiologic aspects such as cerebral blood flow, glucose metabolism, receptor function, and neuroinflammation in schizophrenia. It has supported the dopaminergic hypothesis and helped distinguish symptom types and severity. Diagnostic biomarkers from PET could differentiate schizophrenia from other disorders, while predictive biomarkers might allow earlier targeted treatments. Despite significant promises, the application of PET imaging in schizophrenia is still in its nascent stage, requiring well-designed multicenter studies with large sample sizes to fully realize its clinical potential.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
